Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2019 Earnings Conference Call - Final Transcript

May 08, 2019 • 05:00 pm ET

Previous

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2019 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good day, ladies and gentlemen, and welcome to the First Quarter 2019 Aclaris Therapeutics, Inc. Earnings Conference Call. (Operator Instructions) As a reminder, today's program may be recorded.

I would now like to introduce your host for today's program, Kamil Ali-Jackson, Chief Legal Officer. Please go ahead.

Executive
Kamil Ali Jackson

Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued its press release announcing first quarter 2019 results. For those of you who have not yet seen it, you will find the release posted in the Investors section of our website at www.aclaristx.com.

Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Dr. Stuart Shanler, our Chief Scientific Officer; Frank Ruffo, our Chief Financial Officer; David Gordon, our Chief Medical Officer; and Jeff Wayne, our interim Head of Commercial.

Before we begin our prepared remarks, I would like to remind you that various statements we make during this call about the company's future results of operations and financial position, business strategy and plans and objectives for Aclaris' future operations are considered forward-looking statements within the meaning of the federal securities laws.

Our forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties that could cause actual results to differ materially from those reflected in such statements. These risks are described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations section of Aclaris' Form 10-K for the year ended December 31, 2018, Form 10-Q for the quarter ended March 31, 2019 filed today, and other filings Aclaris makes with the SEC from time to time. These documents are available under the SEC filings section of the Investors page of Aclaris' website at www.aclaristx.com.

All the information we provide on this conference call is provided as of today and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Please be advised that today's call is being recorded and webcast. A link to the webcast is posted in the Investors section of our website. I'll now turn the call over to Dr. Neal Walker, President and CEO of Aclaris. Neal?

Executive
Neal Walker

Thank you, Kamil. Good afternoon everyone and thank you for joining us today for our Q1 call. I will start with a brief update of our business highlights and then touch on a few of our clinical development programs, then I'll hand it off to Stuart Shanler, our Chief Scientific Officer, who will review our clinical development plans and timelines. Jeff Wayne, our interim Head of Commercial, will then address our commercial business, after which Frank Ruffo, our CFO, will review our financial results. Following our prepared remarks, we will open up the line to take your questions. Dr. David Gordon, our Chief Medical Officer, will also be available during the Q&A portion of the call.

Starting with commercial. Today's earnings release highlights our first full